Imat 400mg
Generic: Imatinib
Select Pack Size:
Selected: 30 Tablet/s
$75.00 total
About Imat 400mg
What is Imat 400mg?
Imat 400mg is an Indian brand of imatinib, a kinase inhibitor cancer medicine. Each tablet contains imatinib 400 mg. It is made in India by Zydus Cadila Pharma.
What it is used for
According to the US FDA label for Gleevec (DailyMed), imatinib is used for Philadelphia chromosome positive chronic myeloid leukemia and acute lymphoblastic leukemia, myelodysplastic or myeloproliferative diseases with PDGFR gene rearrangements, aggressive systemic mastocytosis, hypereosinophilic syndrome and chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit (CD117) positive gastrointestinal stromal tumors, including after surgery. Your doctor decides whether it suits you.
Packs and price
Imat 400mg comes in packs of 30, 60 and 90 tablets. The lowest price works out at about $1.81 per tablet on the 90 tablet pack, as of October 2026; the pack selector shows the current price. Shipping is $25 on orders under $149 and free from $149.
Prescription status
Imatinib is a prescription medicine in the US, UK, Australia and Canada. Imat 400mg itself is an India made pack and is not approved by the FDA, MHRA, TGA or Health Canada. The FDA says that importing unapproved medicines for personal use is illegal in most circumstances, so check the rules where you live.
Before you order
Read the patient leaflet that comes with the pack. Tell your doctor or pharmacist about any other medicines you take and any health conditions you have. Get urgent medical help if you notice signs of an allergic reaction, such as swelling of the face, lips, tongue or throat, trouble breathing, or a widespread rash.
Delivery
Orders usually arrive in 7 to 14 business days in plain packaging, with a tracking number.
Key Information
- ✓Active Ingredient: Imatinib
- ✓Category: Life Saving Drugs
- ✓Form: Tablet
- ✓Brand: Imat
- ✓Manufacturer: Zydus Cadila Pharma
Frequently Asked Questions
What is Imat 400mg?
Imat 400mg is an Indian brand of imatinib 400 mg, a kinase inhibitor cancer medicine, made by Zydus Cadila Pharma.
What is Imat 400mg used for?
The US FDA label for Gleevec (DailyMed) lists Philadelphia chromosome positive chronic myeloid leukemia and acute lymphoblastic leukemia, myelodysplastic or myeloproliferative diseases with PDGFR gene rearrangements, aggressive systemic mastocytosis, hypereosinophilic syndrome and chronic eosinophilic leukemia, dermatofibrosarcoma protuberans, and Kit (CD117) positive gastrointestinal stromal tumors, including after surgery. Your doctor decides whether it is right for you.
Do I need a prescription for imatinib?
Imatinib is a prescription medicine in the US, UK, Australia and Canada. This India made pack is not approved by the FDA, MHRA, TGA or Health Canada.
How long does delivery of Imat 400mg take?
Orders usually arrive in 7 to 14 business days in plain packaging, with tracking.
Related Products
View all
Customer Reviews
No reviews yet. Be the first to review Imat 400mg.
Related Articles
Health guides about Imatinib, written by pharmacists
Careprost vs Latisse: Same Bimatoprost 0.03%, What Differs and What It Costs
Careprost and Latisse share the same drug and strength, bimatoprost 0.03%. This guide compares approval, applicators, the Latisse trial results, 2026 US pharmacy costs including cheaper FDA-approved generics, whether insurance or Medicare pays, side effects and who should not use either.
Bimatoprost for Eyebrows: What the Trials Show About Off Label Use
Bimatoprost is FDA approved for eyelashes, not eyebrows, so brow use is off label and rarely discussed properly. A Phase 3 trial and three smaller randomised studies say it works. This guide covers the evidence, a realistic timeline, how brow application differs from lashes, and the risks worth taking seriously.
Latisse vs Bimatoprost Difference: What US Patients Need to Know
Latisse and bimatoprost 0.03% contain the same active ingredient at the same concentration. The latisse vs bimatoprost difference is essentially branding and price. US patients can access generic bimatoprost at significantly lower cost with identical clinical results.